Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

60.34
+0.34000.57%
Pre-market: 61.691.35+2.24%04:22 EDT
Volume:2.32M
Turnover:140.33M
Market Cap:11.68B
PE:402.27
High:61.15
Open:60.37
Low:59.92
Close:60.00
Loading ...

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
12 Mar

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

Benzinga
·
11 Mar

Incyte’s Mixed Trial Results and Strong Financial Position Lead to Hold Rating

TIPRANKS
·
11 Mar

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

Benzinga
·
11 Mar

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

Zacks
·
10 Mar

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

Zacks
·
10 Mar

Positive Outlook for Incyte Amid Mixed TRuE-PN Results and Anticipated Phase III Catalyst

TIPRANKS
·
10 Mar

Incyte (INCY) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
10 Mar

Eli Lilly, Incyte Report Significant Hair Regrowth in Adolescents Treated With Baricitinib

MT Newswires Live
·
10 Mar

Incyte’s Promising Clinical Trials and Strategic Growth Potential Support Buy Rating

TIPRANKS
·
10 Mar

TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)

TIPRANKS
·
10 Mar

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

PR Newswire
·
09 Mar

BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints

Reuters
·
08 Mar

Incyte - Topline Data From Separate Phase 3 Study, True-Pn2, Showed That Primary Endpoint Did Not Reach Statistical Significance

THOMSON REUTERS
·
08 Mar

Incyte Corp - Phase 3 True-Pn1 Study Meets All Primary and Key Secondary Endpoints

THOMSON REUTERS
·
08 Mar

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients With Prurigo Nodularis (Pn) at 2025 American Academy of Dermatology Annual Meeting

THOMSON REUTERS
·
08 Mar